An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects

BACKGROUND AND OBJECTIVES: YLB113 is being developed as a biosimilar of the antitumor necrosis factor-alpha antagonist etanercept, which is approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. An open-label, crossover, ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Shennak, Mustafa, Al-Jaouni, Rana, Kshirasagar, Santhosh, Kasibhatta, Ravi Sekhar, Godse, Neelima, Al-Ghazawi, Ahmad, Vittala, Praveen, Bakhle, Dhananjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359121/
https://www.ncbi.nlm.nih.gov/pubmed/32172488
http://dx.doi.org/10.1007/s13318-020-00613-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359121/
https://www.ncbi.nlm.nih.gov/pubmed/32172488
http://dx.doi.org/10.1007/s13318-020-00613-9

Ejemplares similares